MX379184B - Sal sodica de inhibidor de transportador de acido urico y su forma cristalina. - Google Patents

Sal sodica de inhibidor de transportador de acido urico y su forma cristalina.

Info

Publication number
MX379184B
MX379184B MX2017014319A MX2017014319A MX379184B MX 379184 B MX379184 B MX 379184B MX 2017014319 A MX2017014319 A MX 2017014319A MX 2017014319 A MX2017014319 A MX 2017014319A MX 379184 B MX379184 B MX 379184B
Authority
MX
Mexico
Prior art keywords
sodium salt
uric acid
acid transporter
present
crystalline form
Prior art date
Application number
MX2017014319A
Other languages
English (en)
Other versions
MX2017014319A (es
Inventor
Guaili Wu
Xi Lu
Yunpeng Su
Zhenjun Qiu
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2017014319A publication Critical patent/MX2017014319A/es
Publication of MX379184B publication Critical patent/MX379184B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente invención se relaciona con una sal sódica de un inhibidor de transportador de ácido úrico y la forma cristalina del mismo. En particular, la presente invención se relaciona con la sal sódica de un inhibidor de transportador de ácido úrico (URAT1), el cristal tipo I y el método de preparación del mismo. La presente invención se relaciona con formato de 1-((6-bromo-quinolin-4-il)tio)ciclobutil de sodio (el compuesto de fórmula (I)), y el cristal tipo I y su método de preparación. El cristal tipo I del compuesto de fórmula (I) obtenido en la presente invención tiene buena estabilidad de forma de cristal y estabilidad química, y el solvente de cristalización utilizado tiene baja toxicidad y bajo residuo, y puede utilizarse mejor en el tratamiento clínico. (ver Fórmula).
MX2017014319A 2015-05-27 2016-05-26 Sal sodica de inhibidor de transportador de acido urico y su forma cristalina. MX379184B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510280720 2015-05-27
PCT/CN2016/083423 WO2016188444A1 (zh) 2015-05-27 2016-05-26 一种尿酸转运蛋白抑制剂的钠盐及其结晶形式

Publications (2)

Publication Number Publication Date
MX2017014319A MX2017014319A (es) 2018-03-07
MX379184B true MX379184B (es) 2025-03-10

Family

ID=57393793

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014319A MX379184B (es) 2015-05-27 2016-05-26 Sal sodica de inhibidor de transportador de acido urico y su forma cristalina.

Country Status (22)

Country Link
US (2) US10196361B2 (es)
EP (1) EP3305768B1 (es)
JP (1) JP6738350B2 (es)
KR (1) KR20180006441A (es)
CN (1) CN107001276B (es)
AU (1) AU2016269359B2 (es)
BR (1) BR112017022505A2 (es)
CA (1) CA2984961C (es)
CY (1) CY1123262T1 (es)
DK (1) DK3305768T3 (es)
ES (1) ES2811325T3 (es)
HR (1) HRP20201178T1 (es)
HU (1) HUE051640T2 (es)
LT (1) LT3305768T (es)
MX (1) MX379184B (es)
PL (1) PL3305768T3 (es)
PT (1) PT3305768T (es)
RS (1) RS60749B1 (es)
RU (1) RU2719484C2 (es)
SI (1) SI3305768T1 (es)
SM (1) SMT202000421T1 (es)
WO (1) WO2016188444A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3305768T3 (pl) * 2015-05-27 2020-12-28 Jiangsu Hengrui Medicine Co., Ltd. Sól sodowa inhibitora transportera kwasu moczowego i jego forma krystaliczna
CN108201529B (zh) * 2016-12-16 2021-10-08 江苏恒瑞医药股份有限公司 一种含有尿酸转运蛋白抑制剂的药物组合物及其制备方法
CN110467571B (zh) * 2018-05-11 2021-02-26 江苏恒瑞医药股份有限公司 一种制备环烷基甲酸类衍生物或其可药用盐的方法
WO2025072489A2 (en) 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
MX362747B (es) * 2013-05-13 2019-02-05 Shanghai hengrui pharmaceutical co ltd Derivado de ácido cicloalquilo, método de preparación del mismo, y aplicación farmacéutica del mismo.
PL3305768T3 (pl) * 2015-05-27 2020-12-28 Jiangsu Hengrui Medicine Co., Ltd. Sól sodowa inhibitora transportera kwasu moczowego i jego forma krystaliczna

Also Published As

Publication number Publication date
ES2811325T3 (es) 2021-03-11
EP3305768A4 (en) 2019-02-13
SMT202000421T1 (it) 2020-09-10
KR20180006441A (ko) 2018-01-17
PT3305768T (pt) 2020-08-03
CA2984961A1 (en) 2016-12-01
EP3305768A1 (en) 2018-04-11
US20180134663A1 (en) 2018-05-17
US20190040015A1 (en) 2019-02-07
CN107001276B (zh) 2020-03-13
CY1123262T1 (el) 2021-12-31
HUE051640T2 (hu) 2021-03-01
LT3305768T (lt) 2020-08-25
CN107001276A (zh) 2017-08-01
MX2017014319A (es) 2018-03-07
BR112017022505A2 (pt) 2018-07-17
RU2017142996A (ru) 2019-06-27
JP6738350B2 (ja) 2020-08-12
JP2018515454A (ja) 2018-06-14
DK3305768T3 (da) 2020-08-10
HRP20201178T1 (hr) 2020-11-13
SI3305768T1 (sl) 2020-10-30
RS60749B1 (sr) 2020-10-30
US10196361B2 (en) 2019-02-05
RU2719484C2 (ru) 2020-04-17
RU2017142996A3 (es) 2019-11-20
AU2016269359B2 (en) 2020-02-06
EP3305768B1 (en) 2020-07-01
CA2984961C (en) 2023-08-01
US10358424B2 (en) 2019-07-23
PL3305768T3 (pl) 2020-12-28
AU2016269359A1 (en) 2017-11-23
WO2016188444A1 (zh) 2016-12-01

Similar Documents

Publication Publication Date Title
CA2875877C (en) Syk inhibitors
MY176803A (en) Polymorph of syk inhibitors
CY1123262T1 (el) Αναστολεας metaφopea aλatoς natpioy oypikoy oξeoς kai kpyσtaλλikh mopφh aytoy
AR098110A1 (es) Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina
MY160785A (en) Manufacturing process for pyrimidine derivatives
WO2014128545A3 (en) An improved process for the preparation of dolutegravir
NZ749427A (en) Thiophene, manufacturing method thereof, and pharmaceutical application of same
AU2015306910A8 (en) Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
BR112017018580A2 (pt) p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal
MX394399B (es) Inhibidor de urat1 para promover la excresion de acido urico.
MX373700B (es) Composicion acuosa novedosa.
PH12020500128A1 (en) Inhibitors of ror gamma
MX2011009898A (es) Proceso para la obtencion de derivados de acido propionico.
EP4549450A3 (en) Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts
MX2016015577A (es) La teobromina o sus derivados para el tratamiento o la prevencion de la litiasis renal.
MX2021002896A (es) Proceso para preparar 1-(3,5-diclorofenil)-2,2,2-trifluoroetanona y sus derivados.
MX377314B (es) Sal de un derivado de cefalosporina, forma sólida cristalina del mismo y método para su producción.
EP3272734A8 (en) Ahu377 crystal form, preparation method and use thereof
BR112017005454A2 (pt) composto de l-prolina do inibidor 2 do cotransportador de sódio-glicose, e mono-hidrato e cristal do composto de l-prolina
UY33510A (es) Procedimiento de obtencion de la forma cristalina a del febuxostat
EP3363295C0 (en) COMPOUND FORMULA OF BUTYRATE AND BENZOIC ACID, ITS PREPARATION METHOD AND ITS APPLICATION AS AN ADDITIVE FOR ANIMAL FEED
WO2015084693A3 (en) New process for preparing loratadine from a ketone intermediate
WO2014167509A3 (en) Loxoprofen polymorphs and process for preparation of the same
PH12018501046B1 (en) Crystal of monovalent cation salt of 3-hydroxyisovaleric acid and process for producing the crystals
MD20150099A2 (ro) Formă cristalină a sării de trietilamină a acidului tiazolilacetic substituit